EPS of $-1.23 decreased by 823.5% from previous year
Net income of -8.36M
"Transcript not provided." -
PharmaCyte Biotech Inc (PMCB) QQ1 2026 Results Analysis – Revenue Gap, Large Non-Operating Charge, and Balance Sheet Position in a Cash-Rich Biotech Niche
Executive Summary
PharmaCyte Biotech reported QQ1 2026 with no reported revenue and a net loss of 8.36 million USD, driven predominantly by a substantial non-operating expense of 7.51 million and a negative total other income/expenses of 7.51 million. Operating activity generated a modest cash burn (CFO of -1.99 million) and the company ends the quarter with cash and equivalents of 13.18 million USD. The balance sheet shows a sizable portfolio of long-term investments (24.45 million) and intangible assets (1.55 million), with total assets of 45.11 million and stockholders’ equity of 43.59 million, but retains a meaningful accumulated deficit and a notable non-operating liability structure reflected in the reported metrics. The near-term liquidity remains robust relative to current liabilities, but the path to profitability remains highly dependent on external financing or meaningful scientific milestones. Management commentary (where available) would be pivotal to gauge readiness for potential partnerships, licensing opportunities, or readouts from the CellinaBox platform when and if clinical or preclinical catalysts arise. Absent concrete revenue or binding licensing deals, the core valuation driver remains the company’s ability to secure future funding and monetize its asset base through strategic collaborations or portfolio monetization.
Key Performance Indicators
Operating Income
-848.31K
QoQ: 11.66% | YoY:73.21%
Net Income
-8.36M
QoQ: -174.52% | YoY:-720.65%
EPS
-1.23
QoQ: -179.55% | YoY:-823.53%
Revenue Trend
Margin Analysis
Key Insights
Revenue: None reported in QQ1 2026 (revenue and cost of revenue both listed as null in the data provided).
Operating Income: -0.848 million USD for QQ1 2026, showing a continued operating loss but a modest quarterly deterioration/improvement relative to prior periods as indicated by a QoQ change listed as 11.66% (the negative sign remains, so the QoQ percentage reflects the rate of change in negative territory).
Net Income: -8.360 million USD for QQ1 2026, with YoY and QoQ changes shown as -720.65% and -174.52% respectively, indicating a much larger annual loss versus the prior year, and a largerquarterly loss versus the prior quarter.
EPS (Diluted): -1.23 USD for QQ1 2026, with YoY -823.53% and QoQ -179.55%.
EBITDA: -0.848 million USD, with total other income/expenses net at -7.51179 million USD.
Financial Highlights
Key quarterly metrics and trend context:
- Revenue: None reported in QQ1 2026 (revenue and cost of revenue both listed as null in the data provided).
- Operating Income: -0.848 million USD for QQ1 2026, showing a continued operating loss but a modest quarterly deterioration/improvement relative to prior periods as indicated by a QoQ change listed as 11.66% (the negative sign remains, so the QoQ percentage reflects the rate of change in negative territory).
- Net Income: -8.360 million USD for QQ1 2026, with YoY and QoQ changes shown as -720.65% and -174.52% respectively, indicating a much larger annual loss versus the prior year, and a largerquarterly loss versus the prior quarter.
- EPS (Diluted): -1.23 USD for QQ1 2026, with YoY -823.53% and QoQ -179.55%.
Observations on profitability and cash flow:
- EBITDA: -0.848 million USD, with total other income/expenses net at -7.51179 million USD.
- Net income loss is dominated by non-operating items rather than core operations, given the null revenue and substantive other income/expense line.
- Cash flow from operating activities: -1.99398 million USD; cash at period-end: 13.1783 million USD; cash at beginning: 15.1722 million USD; net change in cash: -1.99386 million, with foreign exchange effects contributing +0.000123 million.
- Free cash flow: -1.99398 million USD (reflecting the operating cash flow and lack of meaningful investing cash flow activity in the period).
- Balance sheet liquidity: total current assets 19.1063 million USD versus total current liabilities 1.060865 million USD, yielding a robust current ratio (~18x) under the quarter’s reported figures.
- Net debt position: net debt is negative (net cash) at -13.1783 million USD, indicating liquidity headroom despite ongoing operating losses.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-848.31K
73.21%
11.66%
Net Income
-8.36M
-720.65%
-174.52%
EPS
-1.23
-823.53%
-179.55%
Key Financial Ratios
Net Income vs. Revenue
Expense Breakdown
Management Commentary
Transcript not provided for QQ1 2026. Without the earnings call transcript, this section cannot include management quotes or thematically grouped takeaways. When available, we will summarize each theme (strategy, operations, market conditions, and catalysts) and attach direct quotes with context and significance.
Transcript not provided.
—
Transcript not provided.
—
Forward Guidance
Management guidance for QQ1 2026 is not disclosed in the data provided. Absent explicit revenue objectives or milestone-based targets, the company’s medium-term outlook hinges on external financing (equity or strategic partnerships) and potential monetization of non-core assets or collaborations related to CellinaBox and other platform assets. Based on the current liquidity (cash and short-term investments totaling roughly 13.4 million USD) and a quarterly operating cash burn around 2.0 million USD, the near-term funding runway is limited absent new financing. Investors should monitor:
- Any announced licensing, collaboration, or milestone-based deals tied to CellinaBox or cannabis-based therapeutics.
- Additional equity financings or debt facilities that would impact dilution and balance sheet leverage.
- Clinical or preclinical readouts that could unlock strategic value or reduce execution risk.
- Updates on capital allocation around long-term investments and intangible assets.
Competitive Position
Company
Gross Margin
Operating Margin
Return on Equity
P/E Ratio
XBIT
0.00%
0.00%
-6.23%
-2.27%
PMVP
0.00%
0.00%
-10.90%
-81.20%
LENZ
0.00%
0.00%
-7.61%
-12.10%
OVID
1.00%
-96.54%
-17.30%
-54.10%
Gross Profit Margin
Operating Profit Margin
Return on Equity
P/E Ratio Comparison
Investment Outlook
PMCB presents a high-risk, high-uncertainty investment profile consistent with many early-stage biotech plays. The QQ1 2026 results show a materially negative bottom line dominated by non-operating charges, with no revenue yet demonstrated. However, the company does possess a sizable asset base (long-term investments and intangibles) and a healthy liquidity cushion, which could enable continued operations and strategic financing scenarios. The investment thesis hinges on the company securing strategic partnerships, licensing agreements, or milestones that unlock value from the CellinaBox platform or related therapies, as well as favorable financing terms that minimize excessive dilution. In the near term, investors should expect continued sensitivity to capital markets conditions and potential equity monetization events. Key catalysts to monitor include potential collaborations, any interim readouts or preclinical milestones, and updates on capital-raising efforts. A disciplined approach would weigh PMCB against peers with clearer revenue pipelines or shorter-path-to-value milestones and benchmark against small-cap biotech cash runway expectations and discipline around dilution.
Key Investment Factors
Growth Potential
The growth potential rests on successful monetization or licensing of the CellinaBox platform and related therapies, plus any progress in Cannabis-derived or diabetes-related applications via partnerships or collaborations. A successful financing round or a strategic deal could unlock material value in the near-to-medium term.
Profitability Risk
Key risks include: (1) no current revenue stream; (2) dependence on future financing and equity dilution; (3) regulatory and clinical development risks inherent in biotechnology; (4) execution risk in converting the asset base (long-term investments, intangibles) into cash or strategic value; (5) potential downward pressure on stock-based compensation and capital structure if dilution occurs.
Financial Position
Cash and cash equivalents of 13.18M USD, plus long-term investments of 24.45M and intangible assets of 1.55M provide a liquidity cushion and asset value. However, accumulated deficit (-93.33M) and reliance on non-operating income to offset losses imply that ongoing funding and strategic partnerships are critical to sustaining operations. Net debt remains negative, indicating a liquidity buffer despite negative operating performance.
SWOT Analysis
Strengths
Robust liquidity position for a micro-cap biotech (cash and equivalents ~13.18M) and net cash position (-13.18M debt).
Material long-term investments (~24.45M) and intangible assets (~1.55M) provide a sizable asset base and optionality.
Low near-term liabilities with no visible debt burden, contributing to a solid balance sheet capacity.
Strategic exposure to CellinaBox platform and potential collaboration opportunities with academic institutions, offering pipeline diversification.
Weaknesses
No reported revenue in QQ1 2026 and a substantial net loss driven by non-operating items, not core operations.
Large accumulated deficit (-93.33M) and potential equity dilution risk given the need for ongoing funding.
Reliance on external financing to sustain operations and advance any clinical or preclinical milestones.